Polycythemia Vera: Barriers to and Strategies for Optimal Management

Overview

Journal Blood Lymphat Cancer

Publisher Dove Medical Press

Specialty Hematology

Date 2023 Dec 26

PMID 38146420

Authors

Andrea Duminuco

Patrick Harrington

Claire Harrison

Natalia Curto-Garcia

Affiliations

Soon will be listed here.

Abstract

Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms characterized by impaired quality of life and severe complications. Despite the increasingly in-depth knowledge of this condition, it necessitates a multifaceted management approach to mitigate symptoms and prevent thrombotic and hemorrhagic events, ensuring prolonged survival. The therapeutic landscape has been revolutionized in recent years, where venesection and hydroxycarbamide associated with antiplatelet therapy have a central role and are now accompanied by other drugs, such as interferon and Janus kinase inhibitors. Ongoing research and advancements in targeted therapies hold promise for further enhancing the therapeutic choice for PV management.

Citing Articles

Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience.

Duminuco A, Bulla A, Rosso R, Romeo M, Cambria D, La Spina E Vaccines (Basel). 2025; 13(2).

PMID: 40006658 PMC: 11860232. DOI: 10.3390/vaccines13020111.

Emergencies in Hematology: Why, When and How I Treat?.

Duminuco A, Del Fabro V, De Luca P, Leotta D, Limoli M, Longo E J Clin Med. 2025; 13(24.

PMID: 39768494 PMC: 11728391. DOI: 10.3390/jcm13247572.

Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults.

Ozygala A, Rokosz-Mierzwa J, Widz P, Skowera P, Wilinski M, Styka B Cancers (Basel). 2024; 16(23).

PMID: 39682300 PMC: 11640741. DOI: 10.3390/cancers16234114.

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.

Duminuco A, Au Yeung J, Vaghela R, Virdee S, Woodley C, Asirvatham S Hemasphere. 2024; 8(8):e143.

PMID: 39131900 PMC: 11310405. DOI: 10.1002/hem3.143.

Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.

Gozzo L, Leotta S, Romano G, Vetro C, Duminuco A, Milone G J Clin Med. 2024; 13(14).

PMID: 39064314 PMC: 11278132. DOI: 10.3390/jcm13144273.

References

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R . Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32(5):1057-1069. PMC: 5986069. DOI: 10.1038/s41375-018-0077-1. View

How J, Story C, Ren S, Neuberg D, Rosovsky R, Hobbs G . Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer J. 2021; 11(11):176. PMC: 8571422. DOI: 10.1038/s41408-021-00566-5. View

Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B . Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia. 2021; 35(10):2989-2993. PMC: 8132485. DOI: 10.1038/s41375-021-01279-1. View

Ianotto J, Curto-Garcia N, Lauermanova M, Radia D, Kiladjian J, Harrison C . Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019; 104(8):1580-1588. PMC: 6669170. DOI: 10.3324/haematol.2018.200832. View

Bou Assi T, Baz E . Current applications of therapeutic phlebotomy. Blood Transfus. 2013; 12 Suppl 1:s75-83. PMC: 3934278. DOI: 10.2450/2013.0299-12. View

Rambaldi A, Iurlo A, Vannucchi A, Martino B, Guarini A, Ruggeri M . Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Blood Cancer J. 2021; 11(3):53. PMC: 7936975. DOI: 10.1038/s41408-021-00445-z. View

Cerquozzi S, Tefferi A . Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015; 5:e366. PMC: 4670948. DOI: 10.1038/bcj.2015.95. View

Mascarenhas J, Kosiorek H, Prchal J, Rambaldi A, Berenzon D, Yacoub A . A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022; 139(19):2931-2941. PMC: 9101248. DOI: 10.1182/blood.2021012743. View

10.

Duminuco A, Nardo A, Garibaldi B, Vetro C, Longo A, Giallongo C . Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting. J Clin Med. 2022; 11(24). PMC: 9783796. DOI: 10.3390/jcm11247418. View

11.

Gavini D, Salvi D, Shah P, Uma D, Lee J, Hamid P . Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review. Cureus. 2021; 13(8):e16978. PMC: 8420994. DOI: 10.7759/cureus.16978. View

12.

Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda J, Ferrer-Marin F . Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2011; 119(6):1363-9. DOI: 10.1182/blood-2011-10-387787. View

13.

Marchetti M, Vannucchi A, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H . Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022; 9(4):e301-e311. DOI: 10.1016/S2352-3026(22)00046-1. View

14.

Steinberg M, Mccarthy W, Castro O, Ballas S, Armstrong F, Smith W . The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010; 85(6):403-8. PMC: 2879711. DOI: 10.1002/ajh.21699. View

15.

Landolfi R, Di Gennaro L . Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008; 93(3):331-5. DOI: 10.3324/haematol.12604. View

16.

Harrison C, Nangalia J, Boucher R, Jackson A, Yap C, OSullivan J . Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023; 41(19):3534-3544. PMC: 10306428. DOI: 10.1200/JCO.22.01935. View

17.

Tefferi A, Fonseca R . Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood. 2002; 99(7):2627. DOI: 10.1182/blood.v99.7.2627. View

18.

De Stefano V, Za T, Rossi E, Vannucchi A, Ruggeri M, Elli E . Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008; 93(3):372-80. DOI: 10.3324/haematol.12053. View

19.

Ianotto J, Couturier M, Galinat H, Mottier D, Berthou C, Guillerm G . Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol. 2017; 106(4):517-521. DOI: 10.1007/s12185-017-2282-5. View

20.

Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V . Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012; 87(5):552-4. DOI: 10.1002/ajh.23160. View